Sunshine Biopharma Inc (SBFM)

[EOT]

$$$$CLINICAL TRIALS HAVE BEGUN $$$$




FINALLY After the 10 years of development they have entered clinical trials, beginning with the xenograft mice.

This is extremely exciting to have a drug 16x better than the only existing drug on the market in clinical trials as we speak.



https://www.sunshinebiopharma.org/

Obviously most intelligent investors are aware that Sunshine Biopharma is the sole owner of world wide patent protection on Adva-27a. And yes they have a address. To funny!!!

https://www.sunshinebiopharma.org/




Anyone interested should read my 3posts...
#44776
#44779
#44781




#1
#44776
The #1drug solution for today’s cancer is
Etoposide.

“”Wikipedia””
Etoposide was approved for medical use in the United States in 1983.[1] It is on the World Health Organization's List of ESSENTIAL MEDICINE, the most effective and safe medicines needed in a health system.[3]



#2
#44779
INITIAL STUDIES.....
June 11, 2011
Sunshine Biopharma's Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells

“”Multidrug Resistant Breast Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is 16-times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug.“”


#3
#44781
Fast forward 10years......

$$CLINICAL TRIALS HAVE BEGUN$$

KABOOOOOM$$$$

XENOGRAFT....means they are NOW using and testing their prepared mice!!!

For Immediate Release October 17, 2019

SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER



Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice. In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors. Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.
About Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. In vitro tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.



Any updates on the ongoing clinical trials and this is in
$$DOLLARS$$